Bayer has developed a system to assess the likelihood of chronic thromboembolic pulmonary hypertension (CTEPH) in patients using imaging studies. The system analyzes characteristics in cardiac, pulmonary, and lung structures to compute the probability of CTEPH. GlobalData’s report on Bayer gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bayer, Peptide pharmacophores was a key innovation area identified from patents. Bayer's grant share as of May 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
Assessing likelihood of chronic thromboembolic pulmonary hypertension using imaging study
A recently granted patent (Publication Number: US12002203B2) outlines a system designed to assess the likelihood of chronic thromboembolic pulmonary hypertension within a patient. The system utilizes an application program stored in memory and executed by a processor to analyze characteristics indicative of the condition within imaging studies of the patient. This involves modifying images from the initial set to identify anatomical structures in the cardiac region, characteristics of the pulmonary vasculature, and chronic abnormalities in the lungs that may suggest the presence of chronic thromboembolic pulmonary hypertension. By assessing these characteristics and computing a likelihood score, the system aims to provide valuable insights into the patient's condition.
The patent details the use of machine learning algorithms to process images and identify target organs like the heart and lungs within the imaging study. Additionally, the system employs various analysis algorithms trained via machine learning to segment images, measure dimensions of anatomical structures, identify perfusion abnormalities in the lungs, and detect vascular abnormalities. By utilizing these advanced technologies, the system can generate a confidence weighting for each characteristic and compute an overall score representing the likelihood of chronic thromboembolic pulmonary hypertension. Furthermore, the system includes a display screen for generating reports on the patient's condition based on the assessment, providing healthcare professionals with valuable information for diagnosis and treatment planning.
To know more about GlobalData’s detailed insights on Bayer, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
